Regeneron struck a $150 million partnership with gene-writing startup Tessera Therapeutics to accelerate Tessera’s platform toward clinical testing. The deal expands Regeneron’s commitment to next-generation genetic medicines and gives Tessera capital and development support as it prepares its first experimental therapy for human trials. Industry observers view the pact as a signal that established biopharma is prioritizing gene‑writing modalities that promise in vivo DNA-level correction. Tessera’s platform focuses on “gene writing,” a technique designed to write or rewrite DNA sequences inside cells without relying on traditional viral vectors. The agreement covers target selection, preclinical development, and options for downstream clinical collaboration. Regeneron’s biochemical and clinical development capacity positions Tessera to move faster toward an IND-stage program.